Literature DB >> 10464902

The safety and success rate of sputum induction using a low output ultrasonic nebuliser.

C J Hunter1, R Ward, G Woltmann, A J Wardlaw, I D Pavord.   

Abstract

Induced sputum differential cell counts have been advocated as a method of non-invasively assessing airway inflammation in asthma and other airway diseases. Since sputum induction usually involves delivering hypertonic saline via a high output ultrasonic nebulizer there have been concerns about its safety in asthma. There are relatively little data on the effects of sputum induction in large numbers of patients. We have examined the success rate and effect of sputum induction on forced expiratory volume in 1 sec (FEV1) in 100 inductions performed on 79 patients using a low output nebulizer. Thirty-seven patients had asthma, 29 had miscellaneous conditions (mainly chronic cough) and 13 were subjects without respiratory symptoms. Sputum was induced 10 min after 200 micrograms of inhaled salbutamol by sequential 5-min inhalations of 3, 4 and 5% saline delivered via a Fisoneb ultrasonic nebulizer and FEV1 was measured after each inhalation. Sputum induction resulted in a sample suitable for analysis in 92% of asthmatics, 90% of those with miscellaneous conditions and 100% of normal subjects. The mean (SEM) maximum per cent fall in FEV1 was 5.4% (0.1), 4.3%, (1.0) and 2.6% (1.1) in subjects with asthma, miscellaneous conditions and in asymptomatic subjects respectively. Only 13 inductions resulted in a > 10% fall in FEV1, and only three of these resulted in a > 20% fall. The maximum per cent fall in FEV1 did not correlate with baseline FEV1 % predicted (r = -0.17), the log sputum eosinophil count (r = -0.12), or the methacholine PC20 (r = -0.14). We conclude that sputum induction using a relatively low output ultrasonic nebulizer with premedication with salbutamol is successful and safe in the majority of patients with asthma and other airway conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464902     DOI: 10.1016/s0954-6111(99)90317-7

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  The use of sputum cell counts to evaluate asthma medications.

Authors:  K Parameswaran; F E Hargreave
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

2.  Safety of sputum induction with hypertonic saline solution in exercise-induced bronchoconstriction.

Authors:  Chris Carlsten; Moira L Aitken; Teal S Hallstrand
Journal:  Chest       Date:  2007-05       Impact factor: 9.410

3.  Comparison of airway immunopathology of eosinophilic bronchitis and asthma.

Authors:  C E Brightling; F A Symon; S S Birring; P Bradding; A J Wardlaw; I D Pavord
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

4.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids.

Authors:  R H Green; C E Brightling; G Woltmann; D Parker; A J Wardlaw; I D Pavord
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

5.  Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus-predominant subgroup.

Authors:  Sarah Diver; Matt Richardson; Koirobi Haldar; Michael A Ghebre; Mohammadali Y Ramsheh; Mona Bafadhel; Dhananjay Desai; Emma Suzanne Cohen; Paul Newbold; Laura Rapley; Paul Rugman; Ian D Pavord; Richard D May; Michael Barer; Christopher E Brightling
Journal:  Allergy       Date:  2019-10-21       Impact factor: 13.146

6.  ATP6V0d2 Suppresses Alveoli Macrophage Alternative Polarization and Allergic Asthma via Degradation of PU.1.

Authors:  Na Liu; Yuchen Feng; Huicheng Liu; Wenliang Wu; Yuxia Liang; Pingfei Li; Zhengping Wei; Min Wu; Zhao Hui Tang; Junyan Han; Xiang Cheng; Zheng Liu; Arian Laurence; Huabin Li; Guohua Zhen; Xiang Ping Yang
Journal:  Allergy Asthma Immunol Res       Date:  2021-05       Impact factor: 5.764

7.  Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing.

Authors:  Simon Couillard; Rahul Shrimanker; Samuel Lemaire-Paquette; Gareth M Hynes; Catherine Borg; Clare Connolly; Samantha Jane Thulborn; Angela Moran; Sarah Poole; Sophie Morgan; Timothy Powell; Ian Pavord; Timothy Hinks
Journal:  Thorax       Date:  2022-07-08       Impact factor: 9.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.